A multicenter, phase II trial of GC1118, a novel anti‐EGFR antibody, for recurrent glioblastoma patients with EGFR amplification

BACKGROUND: We evaluated the therapeutic efficacy of GC1118, a novel anti‐epidermal growth factor receptor (EGFR) monoclonal antibody, in recurrent glioblastoma (GBM) patients with EGFR amplification. METHODS: This study was a multicenter, open‐label, single‐arm phase II trial. Recurrent GBM patient...

Descripción completa

Detalles Bibliográficos
Autores principales: Choi, Seung Won, Jung, Hyun Ae, Cho, Hee‐Jin, Kim, Tae Min, Park, Chul‐Kee, Nam, Do‐Hyun, Lee, Se‐Hoon
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2023
Materias:
RESEARCH ARTICLES
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10469652/
https://www.ncbi.nlm.nih.gov/pubmed/37537946
http://dx.doi.org/10.1002/cam4.6213

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10469652/
https://www.ncbi.nlm.nih.gov/pubmed/37537946
http://dx.doi.org/10.1002/cam4.6213

Ejemplares similares